Obesity Treatment Wegovy
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
First daily pill for weight loss approved by medicines regulator
First daily pill for weight loss approved by medicines regulator The Wegovy semaglutide tablet is taken daily and those with a BMI of 30 or above are eligible - Bookmark - CommentsGo to comments The UK’s first GLP-1 pill for weight loss has been approved by the medicines regulator. The semaglutide tablet, under the brand name Wegovy, is taken daily and obese adults with a body mass index (BMI) of 30 or above qualify.
Weight loss jabs 'should be probed as cancer prevention agents' after US study
Weight loss jabs 'should be probed as cancer prevention agents' after US study Scientists say a new study into weight loss drugs like Mounjaro, Wegovy and Ozempiccan suggest the impact of GLP-1 medicines "may reach further and transform how we think about cancer prevention" Weight loss jabs should be probed as potential "cancer prevention agents", experts say. A study has shown weight loss injections used to tackle obesity and type 2 diabetes - including Mounjaro, Wegovy and Ozempiccan - may...
Breakthrough as UK's first weight loss tablet Wegovy is given green light for use
Breakthrough as UK's first weight loss tablet Wegovy is given green light for use A new prescription-only weight loss tablet has been approved for use in the UK for people who are overweight and have a related condition like high blood pressure The UK's first GLP-1 weight loss pill has been given the green light by the medicines regulator. The Wegovy (semaglutide) tablet, which is taken daily, is for obese adults with a body mass index (BMI) of 30 or above. Those who are overweight and...
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky The same drug that is helping patients manage diabetes and reduce their risk of serious complications from chronic conditions is also being discussed as a beauty hack by people hoping to lose a few kilograms. Experts say more education and awareness are needed.
Scientists discover why ozempic may not work for some people
Scientists discover why ozempic may not work for some people A hidden genetic quirk may be making some people surprisingly resistant to the benefits of blockbuster GLP-1 diabetes drugs. - Date: - June 5, 2026 - Source: - Stanford Medicine - Summary: - Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes.
Weight-loss jabs could slash cancer risk 41 per cent, experts say
Weight-loss jabs could slash cancer risk 41 per cent, experts say A major new study looks at thousands of people taking the medication Weight loss jabs could should be investigated as potential “cancer prevention agents”, experts have said after a study linked the medication to a reduced risk of cancers linked to obesity. Being overweight or obese has been linked to an increased risk of 13 types of cancer including of the breast, bowel, pancreas, kidney, liver and stomach. Glucagon-like...
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
Eli Lilly 's expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to record highs. "It's a parabolic spike. I don't buy parabolas," Jim Cramer said on " Squawk on the Street " on Monday.
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...